medRxiv · 2021 · 51 citations · 31 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccinologyVirologyMrna Vaccine TechnologyVaccinationVaccine DeliveryVaccine EffectivenessVaccine PlatformsViral VaccinesAntigen-antibody RecognitionBreadth Of Antibody ResponseCoronavirus VaccinesHu Antigen ProteinsLipid Nanoparticle DeliveryLipid Nanoparticle Delivery SystemsNanoparticle DeliveryVariant-specific Vaccine Effectiveness
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, new vaccine strategies including lipid nanoparticle delivery of antigen encoding RNA have been deployed globally. The BioNTech/Pfizer mRNA vaccine BNT162b2 encoding SARS-CoV-2 spike protein shows 95% efficacy in preventing disease, but it is unclear how the antibody responses to vaccination differ from those generated by infection. Here we compare the magnitude and breadth of antibodies targeting SARS-CoV-2, SARS-CoV-2 variants of concern, and endemic coronaviruses, in vaccinees and infected patients. We find that vaccination differs from infection in the dominance of IgG over IgM and IgA responses, with IgG reaching levels similar to those of severely ill COVID-19 patients and shows decreased breadth of the antibody response targeting endemic coronaviruses. Viral variants of concern from B.1.1.7 to P.1 to B.1.351 form a remarkably consistent hierarchy of progressively decreasing antibody recognition by both vaccinees and infected patients exposed to Wuhan-Hu-1 antigens.
31
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Victor M. Corman, Olfert Landt, Marco Kaiser et al. · Eurosurveillance · 2020 · 8.2K citations · Full text
Antibody responses to SARS-CoV-2 in patients with COVID-19
Quanxin Long, Bai-Zhong Liu, Haijun Deng et al. · Nature Medicine · 2020 · 3.1K citations · Full text